Abstract:Molecular variants drive tumorigenesis. The degree by which specific molecular variants drive cell proliferation varies between tissues, is dependent upon mutational background within tissues, and also varies along the progression from normal tissue development through cancer growth. Knowledge regarding the magnitude by which variants drive cell proliferation, quantifiable as the scaled selection coefficient or cancer effect size of variants, throughout the trajectory from healthy tissue into cancer informs early cancer evolution, detection, and diagnosis—and also has direct relevance to clinical trials, targeted therapeutics, and basic research prioritization. However, in order to quantify these scaled selection coefficients one must disentangle the prevalence of fixed substitutions from the rate at which they occur within cells—the mutation rate. These mutation rates also vary between tissues, throughout genomes, and over stages of tissue development and carcinogenesis within the same tissue lineage. Here, we present a novel methodology to quantify scaled selection coefficients in a stepwise manner over several discrete steps in tissue evolution and tumorigenesis. We highlight results from ongoing work in two tissue types: the esophagus and the endometrium. Within the normal esophagus and esophageal squamous cell carcinoma we find that mutation rates vary substantially along the trajectory from embryogenesis through normal tissue and from normal tissue through tumorigenesis. Accordingly, we also find that selective advantages vary between these steps of evolution, with variants of NOTCH1, NOTCH2, and FAT1 having measurable proliferative advantage within normal tissues but no detectable proliferative advantage during tumorigenesis, and variants of PIK3CA, TP53, NFE2L2, and FBXW7 being selected to fix within both normal and tumorigenic tissues. Intriguingly, we complement this analysis with a quantification of pairwise epistasis and find that mutation of NOTCH1 decreases the selective advantage of variants within TP53 and other drivers, informing recent research suggesting NOTCH1 substitutions may actively inhibit tumorigenesis. We similarly deconvolute mutation and selection between embryogenesis through atypical hyperplasia of the endometrium and atypical hyperplasia through Stage 1 endometrial carcinoma and find that variants within CTNNB1 and PTEN have higher selective advantage within hyperplasia, whereas variants within ARID1A and PIK3R1 are more highly selected through Stage 1 tumorigenesis. Overall, we demonstrate how accounting for differences in mutational processes and rates among discrete steps in tumorigenesis and epistatic interactions allows one to determine which variants are contributing to clonal expansion within normal tissues, which variants are contributing to tumorigenesis, which variants are important to both, and in certain instances which variants may impede the progression of a tumor. Citation Format: Vincent L. Cannataro, Kira A. Glasmacher, Mary Summers, Jeffrey D. Mandell, J. Nic Fisk, Mia Jackson, Sem Asmelash, Jeffrey P. Townsend. Unraveling mutation and selection to better understand early cancer evolution [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2) nr IA010.

Somatic Evolution in Non-neoplastic IBD-Affected Colon

Intestinal somatic mutations in inflammatory bowel disease patients are enriched in very early onset IBD and primary immunodeficiency genes

Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer

Somatic inflammatory gene mutations in human ulcerative colitis epithelium

Intra-tumour diversification in colorectal cancer at the single-cell level

Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis

Phenotypic plasticity and genetic control in colorectal cancer evolution

and haploinsufficiency equip colonic epithelium for oncogenic transformation

P096 Characterization of suppressive immune cell subsets in mouse models of colitis-associated colorectal cancer

Multi-Omics Characterization of Inflammatory Bowel Disease-Induced Hyperplasia/Dysplasia in the Rag2−/−/Il10−/− Mouse Model

Molecular cartography uncovers evolutionary and microenvironmental dynamics in sporadic colorectal tumors

Somatic mutation and selection at epidemiological scale

OP14 Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencing

Single-Cell Analysis Reveals Unexpected Cellular Changes and Transposon Expression Signatures in the Colonic Epithelium of Treatment-Naïve Adult Crohn's Disease Patients

Antigen-driven expansion of public clonal T cell populations in inflammatory bowel diseases

Identification of Novel Core Genes Involved in Malignant Transformation of Inflamed Colon Tissue Using a Computational Biology Approach and Verification in Murine Models

Association between germline variants and somatic mutations in colorectal cancer

Multiplex spatial omics reveals changes in immune-epithelial crosstalk during inflammation and dysplasia development in chronic IBD patients

The molecular landscape of colitis-associated carcinogenesis

P065 The evolution of inflammatory bowel disease can be monitored through multi-omics characterization of gut tissues

Abstract IA010: Unraveling mutation and selection to better understand early cancer evolution